Physician

Deepak Sambhara, M.D.

According to 2025 Medicare claims, Deepak Sambhara, M.D. (NPI: 1083024574) practices ophthalmology in the Wausau, WI market, with the plurality of this provider's patient population coming from Marathon, WI. This provider's primary affiliated billing organization is EYE CLINIC OF WISCONSIN SC (NPI: 1740263458; TIN: 391093716) and primary practice location at 54403-4754.

Sambhara's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 652 traditional Medicare patients, billed 111,202 HCPCS/CPT codes, and received $4,782,461 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 66 prescription claims across 29 beneficiaries totaling $2,622 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 137 records totaling $258,304. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,930 to $4,782,461. In contrast, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $31,817 to $2,622. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$2.4M$4.8M2018 Medicare payment: $2,930 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $277,123 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,833,526 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,113,492 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,596,757 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $4,359,656 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $4,782,461 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20182639$2,930
20191911,444$277,123
202051110,334$1,833,526
202157610,214$2,113,492
202265525,054$2,596,757
202377795,113$4,359,656
2024652111,202$4,782,461

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$50K$100K2015 Drug cost: $31,817 (USD; Tot_Drug_Cst)2016 Drug cost: $99,827 (USD; Tot_Drug_Cst)2017 Drug cost: $41,081 (USD; Tot_Drug_Cst)2018 Drug cost: $4,019 (USD; Tot_Drug_Cst)2019 Drug cost: $9,941 (USD; Tot_Drug_Cst)2020 Drug cost: $8,504 (USD; Tot_Drug_Cst)2021 Drug cost: $3,081 (USD; Tot_Drug_Cst)2022 Drug cost: $2,238 (USD; Tot_Drug_Cst)2023 Drug cost: $3,372 (USD; Tot_Drug_Cst)2024 Drug cost: $2,622 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015121220$31,817
2016247854$99,827
2017124348$41,081
20183776$4,019
201951119$9,941
202051117$8,504
20214776$3,081
20222969$2,238
20233174$3,372
20242966$2,622

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more5522,202$94
67028Injection of drug into eye5282,262$94
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more161317$57
92134Imaging of retina6202,517$30
J2777Injection, faricimab-svoa, 0.1 mg29396,300$27

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate32951$1,450
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11710$151
LatanoprostLatanoprost11486$90

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.124$166,452Apellis Pharmaceuticals, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.13$91,852Ocular Therapeutix, Inc.
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Deepak Sambhara, M.D.?

Tedicare shows public-source Medicare data for Deepak Sambhara, M.D. (NPI 1083024574), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Deepak Sambhara, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Deepak Sambhara, M.D.?

Deepak Sambhara, M.D. is linked to EYE CLINIC OF WISCONSIN SC (billing NPI 1740263458) in the available physician profile data.

Does Deepak Sambhara, M.D. have Open Payments data?

Deepak Sambhara, M.D. has 137 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.